Reduced Post-transplant Cyclophosphamide Dose in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation for Hematological Malignancies

NCT07193420 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

180

Enrollment

OTHER

Sponsor class

Conditions

GVHD - Graft-Versus-Host Disease
HSCT
Haploidentical Stem Cell Transplantation

Interventions

DRUG: Cyclophosphamide 35mg/kg/day
DRUG: Cyclophosphamide 50mg/kg/day

Sponsor

Assistance Publique - Hôpitaux de Paris